BeiGene
ONC
#682
Rank
S$38.05 B
Marketcap
$336.41
Share price
2.82%
Change (1 day)
71.48%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (ONC) - Cash on Hand

Cash on Hand as of December 2024 : S$3.45 Billion

According to BeiGene 's latest financial reports the company has S$3.45 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

BeiGene - Cash on Hand chart (from 2014 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31S$3.57 B-14.74%
2023-12-31S$4.18 B-31.09%
2022-12-31S$6.07 B-32.05%
2021-12-31S$8.94 B45.41%
2020-12-31S$6.15 B364.38%
2019-12-31S$1.32 B-45.56%
2018-12-31S$2.43 B117.26%
2017-12-31S$1.12 B110.22%
2016-12-31S$0.53 B274.88%
2015-12-31S$0.14 B142.31%
2014-12-31S$58.66 M1079.31%
2013-12-31S$4.97 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
S$21.52 M-99.38%๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.56 B-83.56%๐Ÿ‡บ๐Ÿ‡ธ USA